Since founding Nagourney Cancer Institute (previously Rational Therapeutics) over 20 years ago, Dr. Nagourney, his team, and colleagues have published a number of papers supporting the use of the Ex-Vivo Analysis of Programmed Cell Death (EVA-PCD) functional profiling assay, general cancer research, and the effectiveness of new drugs and combinations.
We have selected our most recent and most prominent papers to make available for download on this site. Click on the image or title in the section below to see each published paper.
Recent Published Peer-Reviewed Articles
D'Amora P, Silva IDCG, Tewari KS, Bristow RE, Cappuccini F, Evans SS, Salzgeber MB, Addis-Bernard PJ, Palma AM, Marchioni DML, Carioca AAF, Penner KR, Alldredge J, Longoria T, Nagourney RA. Platinum resistance in gynecologic malignancies: Response, disease free and overall survival are predicted by biochemical signature: A metabolomic analysis. Gynecol Oncol. 2021 Oct;163(1):162-170. doi: 10.1016/j.ygyno.2021.08.001. Epub 2021 Aug 24. PMID: 34446269.
Nagourney RA, Evans S, Tran PH, Nagourney AJ, Sugarbaker PH. Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin. Eur J Surg Oncol. 2021 Apr;47(4):738-742. doi: 10.1016/j.ejso.2020.09.017. Epub 2020 Sep 19. PMID: 33004272.
D'Amora P, Silva IDCG, Budib MA, Ayache R, Silva RMS, Silva FC, Appel RM, Júnior SS, Pontes HBD, Alvarenga AC, Arima EC, Martins WG, Silva NLF, Diaz RS, Salzgeber MB, Palma AM, Evans SS, Nagourney RA. Towards risk stratification and prediction of disease severity and mortality in COVID-19: Next generation metabolomics for the measurement of host response to COVID-19 infection. PLoS One. 2021 Dec 1;16(12):e0259909. doi: 10.1371/journal.pone.0259909. PMID: 34851990; PMCID: PMC8635335.
Usón Junior PLS, Wagner J, Corpa MVN, Coelho IM, Nagourney RA, Yamaguchi NH. Metastatic carcinoma of unknown primary with complete metabolic response following sorafenib-based chemotherapy. SAGE Open Med Case Rep. 2019 Mar 21;7:2050313X19838739. doi: 10.1177/2050313X19838739. PMID: 30915220; PMCID: PMC6429643.
da Silva I, da Costa Vieira R, Stella C, Loturco E, Carvalho AL, Veo C, Neto C, Silva SM, D'Amora P, Salzgeber M, Matos D, Silva CR, Oliveira JR, Rabelo I, Yamakawa P, Maciel R, Biscolla R, Chiamolera M, Fraietta R, Reis F, Mori M, Marchioni D, Carioca A, Maciel G, Tomioka R, Baracat E, Silva C, Granato C, Diaz R, Scarpellini B, Egle D, Fiegl H, Himmel I, Troi C, Nagourney R. Inborn-like errors of metabolism are determinants of breast cancer risk, clinical response and survival: a study of human biochemical individuality. Oncotarget. 2018 Aug 3;9(60):31664-31681. doi: 10.18632/oncotarget.25839. PMID: 30167086; PMCID: PMC6114970.
Peixoto R, Gomes L, Sousa T, Racy D, Shigenaga M, Nagourney R. Efficacy of oral metformin in a patient with metastatic adrenocortical carcinoma: Examination of mechanisms and therapeutic implications. Rare Tumors. January 2018. doi:10.1177/2036361317749645
Recent Presentations at International Meetings
Nagourney, A D’Amora PA, Silva, ICG, Evans S and Nagourney RA. Complete Remission in Advanced Epithelial Ovarian Cancer Is predicted by Metabolic Signature Measured in the Media of Patient’s Primary Culture 3D Tumor Explants. A Metabolomic Analysis. Proc Amer Assoc Cancer Res. April 12, 2022.
Activity of 3-Bromopyruvate in Human Tumor Primary Culture 3-Dimensional Explants using EX VIVO Analysis of Programmed Cell Death. Adam J. Nagourney, Paulo D’Amora, Steven S. Evans, Paula J. Barnard, Federico R. Francisco, Young Ko, Thomas Stockwell, Maxine Johnson, Robert A. Nagourney. Proc Amer Assoc Canc. Res April 14, 2022.
Nagourney, AJ, Evans SS, Duesberg MS, D’Amora P, Bernard PJ, Francisco F, Nagourney RA. Drugging the Undruggable-Targeting P53: A Comparative Analysis of APR-246 and COTI-2 in human tum or primary culture Explants. Proc Amer Soc of Clin Oncol. June 2022.